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ABSTRACT  
Objective: The introduction of the Hospital Readmission Reduction Program (HRRP) 
has led to renewed interest in developing strategies to reduce 30-day readmissions 
among patients with heart failure (HF). In this study, a model was developed to 
investigate whether the addition of ivabradine to a standard-of-care (SoC) treatment 
regimen for patients with HF would reduce HRRP penalties incurred by a hypothetical 
hospital with excess 30-day readmissions.  
Research design and methods: A model using a Monte Carlo simulation framework 
was developed. Model inputs included national hospital characteristics, hospital-specific 
characteristics, and the ivabradine treatment effect as quantified by a post hoc analysis 
of the Systolic Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT). 
Results: The model computed an 83% reduction in HF readmission penalty payments 
in a hypothetical hospital with a readmission rate of 22.95% (excess readmission ratio = 
1.056 over the national average readmission rate of 21.73%), translating into net 
savings of $44, 016. A sensitivity analysis indicated that the readmission penalty is 
affected by the specific characteristics of the hospital, including the readmission rate, 
size of the ivabradine-eligible population, and ivabradine utilization. Conclusions: The 
results of this study indicate that the addition of ivabradine to an SoC treatment regimen 
for patients with HF may lead to a reduction in the penalties incurred by hospitals under 
the HRRP. This highlights the role ivabradine can play as part of a wider effort to 
optimize the care of patients with HF.  
Keywords: ivabradine; readmissions; heart failure; hospital readmission reduction 
program (HRRP); readmission penalties  
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Introduction 
The Hospital Readmission Reduction Program (HRRP) was added to the Affordable 
Care Act in 2012 to provide a direct financial incentive for hospitals participating in the 
Inpatient Prospective Payment System (IPPS) to reduce readmission rates1,2. The 
program implements penalties based on 30-day all-cause readmissions for five 
conditions: heart failure (HF), acute myocardial infarction, pneumonia, chronic 
obstructive pulmonary disease, and hip or knee replacement. An excess readmission is 
expressed as a ratio, and is defined for each hospital by dividing a hospital’s number of 
predicted 30-day readmissions by the number that would be expected based on an 
average hospital with similar patients: a ratio > 1 would indicate excess readmissions for 
a hospital. The HRRP operates on a 3-year rolling average basis, with penalties 
administered with a 1-year delay. For example, an HRRP penalty for a hospital with 
excessive readmissions in 2016 would reflect the hospital’s performance over the 
3-year period from July 2011 to July 2014. A hospital with higher than national average 
readmissions can be penalized annually at a maximum of 3% of its Medicare diagnosis-
related group (DRG) payments; therefore, reducing 30-day readmission rates has 
become an important objective for US hospitals looking to avoid financial penalties. 
 
To this end, many hospitals have implemented general strategies to reduce 30-day 
readmissions, with an emphasis on improving care both during and after discharge3. 
Predischarge interventions include improvements in patient education, discharge 
planning, and medication reconciliation, and scheduling follow-up appointments before 
discharge. Interventions designed to aid in the transition from hospital to home include 
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providing patient-centered discharge instructions, using transition coaches, and 
attempting to ensure same-provider continuity between inpatient and outpatient care3. 
Postdischarge strategies include timely communication with primary care physicians, 
appropriate clinic follow-up, and follow-up telephone calls with patients3. It has also 
been well documented that the use of such a multitude of strategies is required to have 
a significant impact on readmission rates4,5. 
 
Of the five conditions included in the HRRP, HF is the leading cause of 30-day 
readmissions: 22% of patients are readmitted within this timeframe6. The need for 
readmission has remained high despite the significant improvements made within the 
last two decades in the treatment of HF, including the introduction of therapies such as 
beta-blockers, angiotensin receptor blockers, angiotensin-converting enzyme (ACE) 
inhibitors, and aldosterone antagonists7. Consequently, there is significant interest in 
developing additional strategies to minimize readmissions following HF-associated 
hospitalization to not only control costs, but to also improve patients’ quality of life. In 
fact, quality of life was assessed in a pre-specified substudy of SHIFT and 
demonstrated significant improvement in quality of life during a among patients treated 
with ivabradine vs those treated with placebo when assessed at 4 months, 12 months 
and last post-baseline visit8. This analysis did not specifically assess the impact of 
reduction in hospitalizations, per se, on quality of life; such an assessment is 
appropriate for future research. However, the majority of this research has been 
conducted on the use of multidisciplinary strategies spanning education, postdischarge 
care and monitoring, and communication between hospitals and community care 
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providers, with little emphasis on how specific medical interventions or medication use 
can improve readmission rates9-11. 
 
In patients with HF, a relatively high resting heart rate (HR) (≥ 70 bpm) has been 
identified as a modifiable risk factor that is associated with an increased risk of 
hospitalization and rehospitalization12-14. Ivabradine (Corlanor; Amgen Inc., Thousand 
Oaks, CA), a specific inhibitor of the If current in the sinoatrial node that reduces HR 
without affecting ventricular repolarization or myocardial contractility, was approved in 
April 2015 by the US Food and Drug Administration to reduce the risk of hospitalization 
for worsening HF in patients with stable, symptomatic, chronic HF with left-ventricular 
ejection fraction ≤ 35%, who are in sinus rhythm with a resting HR ≥ 70 bpm and who 
either are receiving maximally tolerated doses of or have a contraindication to beta-
blockers15. This approval was based on the results of the Systolic Heart failure 
treatment with the If inhibitor ivabradine Trial (SHIFT), which showed that treatment with 
ivabradine in combination with guideline-based standard-of-care (SoC) therapy was 
associated with a relative risk reduction of 11% for all-cause hospitalization and 26% for 
HF-related hospitalization16. A subsequent post hoc analysis of the SHIFT data also 
indicated that treatment with ivabradine led to a substantial reduction in the risk of 
rehospitalization for worsening HF17; therefore, ivabradine represents a potential 
strategy for reducing 30-day readmission rates for patients with HF. Because the effect 
of ivabradine on 30-day readmissions and the resulting potential reductions in financial 
penalties associated with these readmissions has not yet been investigated, the aim of 
this study was to develop a model for a hypothetical hospital with excess readmissions 
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to evaluate the potential change in HRRP penalties associated with adding ivabradine 
to SoC therapy, compared with SoC alone. 
Methods 
Overview 
A Monte Carlo simulation model was developed to quantify the potential financial impact 
of ivabradine on reducing all-cause 30-day readmissions following an HF admission for 
a hypothetical hospital under the HRRP. The model first computed the total HRRP 
penalties for the hospital, based on its rates of excess readmission. The model then 
applied the utilization rate of ivabradine and the effect of ivabradine on 30-day 
readmission rates to calculate the reduction in readmission associated with the addition 
of ivabradine to SoC therapy. Finally, the model translated the reduction in 30-day 
readmission with ivabradine into a reduction in the HRRP penalty.  
Model structure  
The HRRP model simulated the rate of 30-day readmission with and without ivabradine 
for a hypothetical hospital in the middle of the penalty range. Figure 1 shows the 
distribution readmission rates of the hospitals participating in the HRRP, as published 
by the Centers for Medicare & Medicaid Services (CMS): the hospitals above the 
national average (21.73%) are penalized. For the purpose of this study, the example 
hospital in the middle of the penalty range, which eventually is at the 75th percentile. To 
account for the distribution of the potential effects of ivabradine on readmission rates, 
the model used a Monte Carlo simulation framework (1000 replications) that estimated 
the range of potential reductions in excess readmissions and HRRP penalties. Each 
replication of the Monte Carlo simulation took a sample from the readmission rate 
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reduction distribution, and then adjusted the readmission rate reduction for ivabradine 
compared with SoC to compute an effective reduced hospital readmission rate. If the 
reduction did not bring the 30-day readmission rate below the national average (the 
point at which the penalty is completely eliminated), the model computed the reduced 
HRRP penalty with the adjusted readmission rate based on the HRRP algorithm 
published by the CMS1,2.  
Model inputs 
The model inputs were divided into three groups: national-level characteristics, hospital-
specific characteristics (for the example hospital), and treatment effect of ivabradine. 
The model simulated HRRP penalties for a hypothetical hospital with and without the 
use of ivabradine. Thus, the model input the characteristics of the hypothetical hospital, 
compared these characteristics to the national average, and then applied the treatment 
effect of ivabradine on readmissions. The hypothetical hospital was assumed to reflect 
the national average in terms of case mixture and reimbursements, with a readmission 
rate at the middle (75th percentile) among hospitals penalized for readmission following 
HF admission.  
National hospital characteristics 
The national total annual DRG payments for all discharges for 2010–2014 were taken 
from the Medicare Payment Advisory Commission data on Medicare total payment for 
fee-for-service beneficiaries for inpatient services in acute care hospitals1,2; these data 
were used to compute the national average annual DRG payment for all discharges, 
which was $117 billion. The national payment per HF discharge was computed from 
data provided in the CMS acute IPPS final rule and the national average payment table 
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from OPTUM/INGENIX for 2010–201318, and was used to estimate the national average 
payment per HF discharge, which was $6285. The national total number of HF 
discharges was 1, 097, 144 and the national average readmission rate was 21.73%; 
these were estimated based on the latest HRRP data provided by CMS from July 2011 
to July 2014 (Table 1). 
Hospital-specific characteristics 
Readmission penalties are dependent on the hospital’s excess readmission ratio. The 
excess readmission ratio was determined by the specific characteristics of the hospital 
being evaluated. For the hypothetical hospital in this analysis, the excess readmission 
ratio was selected using an all-cause readmission rate of 22.95%, which was divided by 
the national average HF readmission rate of 21.73%. Thus, the excess readmission 
ratio for the hypothetical study hospital was 1.056, which was around the 75th percentile 
of national distribution. The HRRP model estimated the hospital’s total annual payments 
for all discharges by computing its ratio relative to the national average total annual 
DRG payments. Furthermore, the hypothetical hospital was assumed to have 150 
annual HF admissions, and its total annual HF DRG payment was estimated by 
multiplying its annual HF admission with the national average payment per HF 
discharge ($6285). For the purpose of this model, an ivabradine utilization scenario of 
100% among readmitted patients was assumed. The size of the eligible patient 
population and ivabradine utilization rate were chosen to simplify interpretation of the 
base-case results (Table 1) and then tested in sensitivity analyses. In summary, the 
hypothetical hospital with an excess readmission ratio of 1.056 closely corresponded to 
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the median hospital in the penalty range for HF. The HRRP hospital readmission rates 
provided by the CMS for 2011–2014 are shown in Figure 1.  
Treatment effect of ivabradine 
To estimate the impact of ivabradine on 30-day all-cause readmission rate reduction, a 
post hoc analysis of SHIFT data was conducted. A Bayesian approach was chosen to 
quantify the probability of a reduction in readmission over a range of effect sizes and to 
study the effect of uncertainty on reduction in HRRP penalties. This approach was 
selected because it focuses directly on the probability of observing a given treatment 
effect based on the available data, rather than on disproving a hypothesis of no 
treatment effect. The model then uses the full range of potential treatment effects 
weighted by their computed probabilities instead of a single point estimate, providing 
more flexibility in describing the range of potential benefit or cost. Bayes theorem 
assigns a probability to a hypothesis directly and incorporates prior available information 
(as probabilities), which is then updated with the new evidence. For the purpose of this 
analysis, noninformative prior distributions were used; in other words, the results of the 
analysis were informed by SHIFT data only. All Institutional Review Boards at the each 
of the participating sites approved the study and all patients provided consent. All 
inferences were made based on the posterior distributions; the mean provided a point 
estimate, and the 2.5th and 97.5th percentiles were used to create 95% credible intervals 
(CrIs). All analyses were performed using the GENMOD procedure with the Bayes 
statement in SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).  
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The post hoc analyses using patient-level SHIFT trial data for 30-day all-cause 
readmission yielded a rate difference (RD) (95% CrI) of −1.97% (−6.29, 2.39) for 
ivabradine compared with placebo, ie, the use of ivabradine was associated with 
avoiding 30-day readmissions in a mean of 1.97% of patients with an initial HF-related 
hospitalization. The probability of observing an RD that was negative (ie, a reduction of 
some magnitude in 30-day readmissions) was 82%, while the probability of observing 
an RD of less than −2% was 50% (Table 2). The cumulative distribution function of all-
cause readmission rate reduction for ivabradine compared with SoC treatment is shown 
in Figure 2. 
Model assumptions 
As with any model, the HRRP model relied on a set of assumptions. Most importantly, 
the analysis also assumed that the absolute reduction in 30-day all-cause readmission 
rate with ivabradine estimated using SHIFT data would translate to the real-world US 
clinical practice setting. In the absence of US-specific data for ivabradine’s effect on 
readmissions, this assumption was selected to be more conservative (ie, less favorable) 
to ivabradine. Because 30-day readmission rates in the US claims data are higher 
compared with those in SHIFT1,2,17, a relative risk-based approach would have resulted 
in a larger absolute treatment effect. The potential effect of ivabradine was only 
considered on readmissions for patients who had an initial hospitalization: its effect on 
initial HF admissions was not included. This was also a conservative assumption 
regarding the effect of ivabradine on penalties, as a reduction in the number of patients 
at risk of readmission would also lower the absolute readmission penalty. 
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Finally, it was assumed that the ivabradine utilization and rate of all-cause readmissions 
would be constant over the 3-year time horizon from which readmission rates are 
averaged in the HRRP. These assumptions were made to simplify the analyses and 
presentation of results, and do not alter the results for any individual year. Similarly, the 
model assumed that the penalties for the HRRP conditions other than HF would remain 
unaffected by ivabradine over this period. Unless a hospital is at or near the ceiling for 
the overall HRRP penalty, changes in the non-HF components would not affect the HF 
penalty. 
Results 
HRRP penalty reduction results 
After applying the reduction in 30-day readmissions (absolute −2% reduction with a 
probability of 50%; corresponding to preventing three readmissions in the example 
hospital with 150 initial HF admissions) due to ivabradine, the excess readmission ratio 
for the example hospital was reduced from 1.056 to 1.0093 (Table 3). This reduction in 
excess readmission ratio translates into an 83% reduction in HF readmission penalty 
payments in the example hospital. The 83% reduction in penalty equates to $44, 016, 
which would be incurred over 3 years when applying the median readmission rate 
reduction with ivabradine (Table 4).  
Sensitivity analyses 
The fraction by which the penalty would be reduced decreases for a hospital with a 
higher rate of excess readmissions, as the effects of ivabradine are considered to be an 
absolute RD (Figure 3). If a hospital has an excess readmission ratio of 1.2, the model 
predicts an HRRP penalty reduction of 25%. As the excess readmission rate gets closer 
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to 1, the proportion of penalty reduction approaches 100%. Figure 4 illustrates a tornado 
diagram on reduction in HRRP penalty for three scenarios: ivabradine utilization (50%, 
100%), ivabradine eligibility (25%, 75%), and cohort selection in the post hoc SHIFT 
analyses (excluding no patients, except for patients who died during the index 
hospitalization). In the base case, 100% (upper bound) ivabradine utilization was 
considered where the penalty reduction was ~83%. When the ivabradine utilization is 
reduced to 50% (lower bound), in the one-way sensitivity analyses the penalty reduction 
would be 42%. In other words, hospitals with smaller ivabradine-eligible populations or 
with lower utilization of ivabradine would similarly have smaller predicted reductions in 
the penalty. 
Discussion 
The model developed within this analysis indicates that the addition of the HR-lowering 
drug ivabradine to an SoC treatment regimen for patients with HF could substantially 
reduce the penalty incurred by a hospital under the HRRP, though this benefit may be 
specific to patients with HF, given that ivabradine did not affect hospitalization for new-
onset or worsening of HF in patient populations defined as chronic stable coronary 
artery disease not meeting the inclusion criteria for SHIFT19. It should be noted that the 
sensitivity analysis indicated that the readmission penalty was affected by the specific 
characteristics of each hospital, and therefore that the estimated effect on the penalty 
only directly applies to the hypothetical hospital considered here; yet, the results likely 
indicate a potential real-world benefit. To our knowledge, this is the first study that has 
been carried out to analyze the potential financial benefits of adding ivabradine to an 
SoC regimen for patients with HF in light of the penalties implemented under the HRRP.  
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The introduction of the HRRP has intensified interest into strategies that can be used to 
reduce 30-day readmissions, particularly for patients with HF due to their high 
readmission rate. A number of general strategies have been shown to have some 
success in reducing readmission rates, including partnering with community physicians, 
partnering with local hospitals, having nurses perform medication reconciliation, 
arranging follow-up appointments before discharge, having a process in place to send 
all relevant discharge information to the patient’s primary care physician, and assigning 
staff to follow-up on test results that return following discharge10. However, due to the 
variable implementation of such strategies and the large number of factors involved in 
readmission, the benefits of introducing such interventions has remained modest5,9. In 
contrast to these general interventions, the model developed within this study 
considered a strategy highly specific to patients with HF. The results indicate that 
addition of ivabradine to an SoC regimen has the potential to reduce penalties incurred 
under the HRRP, and suggest that HF-specific medication-based strategies may also 
improve readmission rates. While several other studies investigating the benefits of 
medications have suggested that diuretics, mineralocorticoid antagonists, ACE 
inhibitors, and digoxin may also improve readmission rates, none have modeled the 
potential financial benefits of their use in light of the HRRP20-22.  
 
While the model developed herein suggests that the addition of ivabradine to an SoC 
regimen may avoid penalties by reducing readmission rates, it must be emphasized that 
the implementation of this strategy in conjunction with other, more general strategies will 
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likely provide more substantial cost savings. This can be assumed on the basis that the 
hospitals that are most successful in reducing readmission rates have implemented 
multiple strategies, with the greatest improvements seen with those using three or 
more4,23. Future studies should consider the addition of ivabradine to an SoC regimen 
as part of a system-wide approach that utilizes a range of risk-reduction strategies. 
Whether the inclusion of a medication-based strategy could provide benefits beyond 
those achieved using general strategies alone, is also worth considering.  
 
This model has a number of strengths. Firstly, an appropriate statistical approach was 
used to extract the probability distribution for an ivabradine effect on readmission rates 
from the SHIFT data. As mentioned earlier, a Bayesian approach was selected because 
it focuses directly on the probability of observing a given treatment effect based on the 
available data, rather than on demonstrating that the effect is likely to be nonzero. 
Therefore, the model uses the full range of potential treatment effects weighted by their 
computed probabilities, rather than a single point estimate. Utilizing the full probability 
distribution for changes in 30-day readmission rate weighted by a probability of its 
occurrence allows for a more complete picture of the range of potential outcomes an 
individual hospital might expect. The second strength of the model is that the 
readmission penalty was computed in the model following the CMS procedure for an 
individual hospital and using US hospital readmission data, which have the most direct 
relevance to the hospital.  
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However, there are several limitations. The 30-day readmission practices used in this 
analysis may vary from that the real-world setting, as may the clinical characteristics of 
the patients within the SHIFT study; yet ivabradine has been available to a wider patient 
population in Europe since 2005, and the tolerability profile remains remarkably 
unchanged24. The model also relates to the assumption of 100% utilization of ivabradine 
in readmitted patients—in the real world, it would be unlikely for all patients who would 
be readmitted within 30 days of the initial HF hospitalization discharge to be eligible for 
ivabradine treatment. There is a lack of literature regarding specific demographic and 
clinical characteristics of patients who are readmitted, and therefore a 100% utilization 
rate was chosen to simplify interpretation of the base-case results, and then, a range 
was tested in sensitivity analyses. Finally, it should also be noted that the readmission 
penalty is applied on a 3-year rolling basis, and changes in the utilization of ivabradine 
or the eligible population over the 3-year rolling period would alter its impact on the 
penalty. A real-world analysis would validate these findings. Changes in the national 
landscape may also influence the penalty assessed, even if there are no changes at an 
individual hospital.  
 
Conclusion 
The results of this study indicate that reducing 30-day readmissions by adding 
ivabradine to an SoC treatment regimen may lead to a reduction in the penalties 
incurred by hospitals under the HRRP. This highlights the role ivabradine can play as 
part of a wider effort to optimize the care of patients with HF.  
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Figure legends 
Figure 1. Hospital Readmission Reduction Program hospital readmission rates for 2011 
to 2014. 
Figure 2. The cumulative distribution function of all-cause readmission rate reduction 
for ivabradine vs standard of care (SoC).  
Figure 3. Computed Hospital Readmission Reduction Program (HRRP) penalty savings 
in heart failure readmission penalty payments for hospitals with different excess 
readmission rates.  
Figure 4. Tornado diagram on reduction in Hospital Readmission Reduction Program 
(HRRP) penalty.  
 
 
 
  
  
 
Tables 
Table 1. Model inputs for national and hospital-specific characteristics. 
Input Parameter Estimate 
National HRRP hospital characteristics 
National average total annual DRG payments for all 
discharges $117, 000, 000, 000 
National average payment per HF discharge (2011-2013) $6285 
National total number of HF discharges (2011-2013) 1, 097, 144 
National average HF readmission rate (2011-2013) 21.73% 
Hospital characteristics  
Hospital total annual number of HF admissions 150 
Hospital HF excess readmission ratio 1.056 
Hospital HF readmission rate 22.95% 
Hospital total annual HF DRG payments $942, 750 
Share of this hospital from all HRRP hospitals 0.041% 
Hospital total annual DRG payments for all discharges $47, 988, 231 
DRG, diagnosis-related group; HF, heart failure; HRRP, Hospital Readmission 
Reduction Program.  
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Table 2. Thirty-day readmission rates for patients in the SHIFT study for all-cause 
readmission after an admission for HF. 
 
Treatment 
Patients at Risk 
of Readmission 
n 
Rate of Readmission 
Within 30 days 
Mean (95% CrI) 
Posterior Probabilities of RD 
p (RD < −2.0%) p (RD < 0%) 
Ivabradine 479 15.05% (12.00, 18.36) 
50% 82% Placebo 623 17.02% (14.17, 20.09) 
CrI, credible interval; HF, heart failure; RD, rate difference; SHIFT, Systolic Heart 
Failure Treatment with the If Inhibitor Ivabradine Trial.  
  
  
 
Table 3. Reduction in readmission rates due to use of ivabradine. 
Parameter Change 
Median readmission rate change for ivabradine vs SoC  −2.03% 
Probability to observe the median rate change 50.0% 
Eventual readmission rate change  −1.01% 
Hospital ivabradine utilization (assumption) 100.0% 
Hospital effective readmission rate change for eligible patients −1.01% 
Hospital HF readmission rate with ivabradine*  21.93% 
Hospital HF excess readmission ratio without ivabradine 1.056 
Hospital HF excess readmission ratio with ivabradine 1.0093 
HF, heart failure; SoC, standard of care. 
*For the example hospital with an HF readmission rate of 22.95%. 
 
  
  
 
Table 4. Savings in reimbursement penalties due to the use of ivabradine. 
Results SoC Ivabradine 
Penalty payments for risk-adjusted excess HF readmissions $52, 794 $8778 
Hospital-specific readmission payment adjustment factor 99.8900% 99.9817% 
Reduction amount for excess readmissions (97% floor) $52, 794 $8778 
Net savings in penalty payments n/a $44, 016 
Percentage reduction in HF readmission penalty payments  n/a 83.37% 
HF, heart failure; n/a, not available; SoC, standard of care. 
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Figure 2. 
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Figure 3. 
 
 
  
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1 1.05 1.1 1.15 1.2 1.25 1.3
%
 R
ed
u
ct
io
n
 in
 H
R
R
P
 P
en
al
ty
Excess Readmission Rate
29 
 
Figure 4.  
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